The COVID-19 Vaccine Patent Waiver: The Wrong Tool for the Right Goal
Creative Commons Attribution 4.0 International License (CC-BY 4.0)?
No comments here
Why not start the discussion?
Skip to main content
Reviews of "The COVID-19 Vaccine Patent Waiver: The Wrong Tool for the Right Goal"
Reviewers: Gaétan de Rassenfosse (Harvard) | 📗📗📗📗◻️ • Keith Maskus (UC Berkeley) | 📒📒📒◻️◻️
Published onJul 05, 2021
Reviews of "The COVID-19 Vaccine Patent Waiver: The Wrong Tool for the Right Goal"
To read the original manuscript, click the link above.
Summary of Reviews: Reviewers find this a well-written opinion piece on the limitations of patent waivers to increase global vaccine coverage; however, they find that this piece would benefit from more empirical references and a more substantial discussion of possible policy and market alternatives.
Reviewer 1 (Gaétan de Rassenfosse) | 📗📗📗📗◻️
Reviewer 2 (Keith Maskus) | 📒📒📒 ◻️◻️
RR:C19 Strength of Evidence Scale Key 📕 ◻️◻️◻️◻️ = Misleading 📙📙 ◻️◻️◻️ = Not Informative 📒📒📒 ◻️◻️ = Potentially Informative 📗📗📗📗◻️ = Reliable 📘📘📘📘📘 = Strong |
To read the reviews, click the links below.
